2. Search Result
Search Result
Results for "

cataract formation

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

1

Biochemical Assay Reagents

1

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-19696B
    Tauroursodeoxycholate dihydrate
    100+ Cited Publications

    Tauroursodeoxycholic acid dihydrate; TUDCA dihydrate; UR 906 dihydrate

    		 Caspase Apoptosis Endogenous Metabolite IRE1 NF-κB JNK Reactive Oxygen Species (ROS) Akt Neurological Disease Metabolic Disease Inflammation/Immunology
    Tauroursodeoxycholate dehydrate is an orally active taurine conjugate of Ursodeoxycholic acid (HY-13771). Tauroursodeoxycholate dehydrate inhibits caspase-3/7, Apoptosis, IRE1α/TRAF2/NF-κB, prevents JNK phosphorylation, inhibits ROS generation, and activates Akt signaling. Tauroursodeoxycholate dehydrate prevents cataract formation, reduces renal tubular damage in type 2 diabetic mice, reduces I/R injury in liver, and inhibits intestinal inflammation and barrier disruption in nonalcoholic fatty liver disease .
    Tauroursodeoxycholate dihydrate
  • HY-Y0785
    Glyoxal (40% w/w in water)

    		Drug Metabolite Metabolic Disease
    Glyoxal is a cytotoxic α-oxoaldehyde. Glyoxal induces cell damage and promotes protein glycation to form advanced glycation end-products (AGEs). Glyoxal is promising for research of oxidative stress-related diseases (such as atherosclerosis, cataract, Alzheimer's disease), and the formation of calcium oxalate kidney stones .
    Glyoxal (40% w/w in water)
  • HY-Y0785S
    Glyoxal-d2

    		Isotope-Labeled Compounds Drug Metabolite Metabolic Disease
    Glyoxal-d2 is the deuterium labeled Glyoxal (HY-Y0785). Glyoxal is a cytotoxic α-oxoaldehyde. Glyoxal induces cell damage and promotes protein glycation to form advanced glycation end-products (AGEs). Glyoxal is promising for research of oxidative stress-related diseases (such as atherosclerosis, cataract, Alzheimer's disease), and the formation of calcium oxalate kidney stones .
    Glyoxal-d2
  • HY-185048
    PCB-OAA

    		Drug Intermediate Neurological Disease
    PCB-OAA is a biocompatible multivinyl polycarboxybetaine macromonomer and that exhibits anti-fouling activity. PCB-OAA can form a hydrogel in vitreous cavity and shows an appealing ability to prevent significantly inflammatory response, fibrosis and complications such as raised intraocular pressure, and cataract formation. PCB-OAA can be used for the research of vitreous substitution .
    PCB-OAA
  • HY-106198
    Lidorestat

    IDD-676

    		 Aldose Reductase Metabolic Disease
    Lidorestat (IDD-676) is a potent, selective and orally active aldose reductase inhibitor with an IC50 of 5 nM. Lidorestat can be used for chronic diabetes complications. Lidorestat also improves nerve conduction and reduces cataract formation .
    Lidorestat
  • HY-106198R
    Lidorestat (Standard)

    IDD-676 (Standard)

    		 Reference Standards Aldose Reductase Metabolic Disease
    Lidorestat (Standard) is the analytical standard of Lidorestat (HY-106198). This product is intended for research and analytical applications. Lidorestat (IDD-676) is a potent, selective and orally active aldose reductase inhibitor with an IC50 of 5 nM. Lidorestat can be used for chronic diabetes complications. Lidorestat also improves nerve conduction and reduces cataract formation .
    Lidorestat (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: